Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $25.7143.

Several brokerages recently weighed in on DAWN. TD Cowen began coverage on shares of Day One Biopharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Day One Biopharmaceuticals in a research report on Monday, November 24th. Piper Sandler raised their price objective on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Zacks Research raised shares of Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th.

Insider Buying and Selling at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 6,065 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Adam Dubow sold 6,395 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the completion of the transaction, the insider directly owned 72,694 shares in the company, valued at $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Day One Biopharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after buying an additional 1,029 shares during the last quarter. Federated Hermes Inc. purchased a new stake in Day One Biopharmaceuticals during the 3rd quarter valued at approximately $39,000. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth approximately $49,000. Ameritas Investment Partners Inc. grew its stake in shares of Day One Biopharmaceuticals by 44.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after purchasing an additional 2,051 shares during the period. 87.95% of the stock is owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $11.78 on Friday. The stock has a 50 day moving average price of $10.48 and a 200 day moving average price of $8.63. Day One Biopharmaceuticals has a one year low of $5.64 and a one year high of $13.20. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -7.75 and a beta of -1.26.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.